Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Shufeng Jiedu Granules for mild COVID-19
ChiCTR2300076084Phase 3Not yet recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Sep 2023
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Shufeng Jiedu in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Time from initiation of treatment to sustained clinical recovery of COVID-19-related symptoms. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
Shufeng Jiedu
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2300076084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300076084.